|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-5-1
|
|
pubmed:abstractText |
The aim of this study was to determine the efficacy and toxicity of single agent off-protocol, liposomal doxorubicin (Doxil Alza), in consecutive patients with recurrent ovarian cancer and to investigate the influence of HER-2/neu expression on response to liposomal doxorubicin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2001 Academic Press.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
81
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
206-12
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:11330951-Adult,
pubmed-meshheading:11330951-Aged,
pubmed-meshheading:11330951-Antibiotics, Antineoplastic,
pubmed-meshheading:11330951-Doxorubicin,
pubmed-meshheading:11330951-Female,
pubmed-meshheading:11330951-Humans,
pubmed-meshheading:11330951-Liposomes,
pubmed-meshheading:11330951-Middle Aged,
pubmed-meshheading:11330951-Neoplasm Recurrence, Local,
pubmed-meshheading:11330951-Ovarian Neoplasms,
pubmed-meshheading:11330951-Receptor, erbB-2,
pubmed-meshheading:11330951-Retrospective Studies
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
|
|
pubmed:affiliation |
Dana Farber Cancer Institute and the Brigham and Women's Hospital, Boston, MA 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
